# A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

> **NCT03982199** · PHASE2 · TERMINATED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 5815 (actual)

## Conditions studied

- Respiratory Syncytial Viruses
- Respiratory Tract Diseases

## Interventions

- **BIOLOGICAL:** RSV Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03982199
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-01
- **Primary completion:** 2022-06-06
- **Final completion:** 2023-05-26
- **Target enrollment:** 5815 (ACTUAL)
- **Why stopped:** The study was terminated early by the sponsor due to strategic reprioritization reasons.
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982199, "A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03982199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*